Seegnal Inc. Receives Gold Mark from the Standards Institution of Israel, Advancing Commercialization Readiness

Seegnal Inc. Receives Gold Mark from the Standards Institution of Israel, Advancing Commercialization Readiness

Triple ISO Certification Recognition Positions Company as a Standard-Bearer in Clinical Decision Support Quality Infrastructure

Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Company"), a global leader in clinical decision support solutions applying patient-centric medication safety standards, today announced that Seegnal eHealth Ltd., its Israeli operating subsidiary, has been granted the prestigious Gold Mark by the Standards Institution of Israel, a high institutional quality distinction awarded to organizations that have embedded a culture of excellence across their management systems, processes, and product lifecycle. The Gold Mark certification further solidifies Seegnal's commercialization-readiness and its standing as an enterprise-grade platform trusted by leading healthcare systems.

A Landmark Recognition in Quality Leadership
The Gold Mark is conferred exclusively upon organizations that have adopted quality and excellence as a foundational organizational ethos, not merely as a compliance exercise, and that simultaneously hold three or more quality certification marks attesting to the alignment of their management systems, processes, and products with Israeli and international standards. It represents the intersection of institutional rigor, operational discipline, and an unwavering commitment to safety and performance.

Seegnal eHealth Ltd. received the Gold Mark in recognition of holding all three of the following certification marks, each issued by the Standards Institution of Israel:

  • ISO 13485:2016: Medical Devices Quality Management Systems, certifying that Seegnal's quality management processes meet the most demanding international standards applicable to medical device manufacturers and suppliers;
  • ISO 27799: Information Security Management in Health, confirming that Seegnal's data governance and information security architecture conform to sector-specific requirements for the handling of sensitive health data; and
  • ISO 27001:2022: Information Security Management Systems (ISMS), attesting to a certified and independently audited information security management framework across the organization.

The Gold Mark certificate for 2026 was signed by Dr. Gilad Golub, CEO of the Standards Institution of Israel, and Avital Weinberg, VP of the Quality & Certification Division.

About Seegnal Inc.
Seegnal Inc. (TSXV: SEGN) is a global leader in clinical decision support, applying patient-centric medication safety standards to improve outcomes across healthcare systems. Seegnal's proprietary platform is deployed at leading hospital networks and provides real-time, point-of-care medication safety intelligence. For more information, visit www.seegnal.com.

Contact Information
Elad Bibi-Aviv
Chief Executive Officer
+1 (929) 248 4652
Arx Investor Relations
North American Equities Desk
seegnal@arxhq.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Source

SEGN:CA
The Conversation (0)
Lexaria Bioscience Corp. (Nasdaq: LEXX)

Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property

Lexaria Bioscience Corp. (Nasdaq: LEXX), (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the engagement of the contract research organization (“CRO”) to execute and report on its 2026 animal Study #1 (GLP-1-A26-1) that will evaluate a number of... Keep Reading...
Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property

Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property

Contracts signed for Animal Study GLP-1-A26-1 KELOWNA, BC / ACCESS Newswire / April 15, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce the engagement of the contract research organization ("CRO")... Keep Reading...
Microscope and syringe overlay a digital stock chart with green lines and numbers.

Kailera, Alamar Target Billion-Dollar Valuations in Biotech Revival

Biotechnology initial public offerings (IPOs) are regaining momentum as easing market headwinds and an appetite for weight-loss drugs coax companies back to the public markets.On Monday (April 13) Reuters reported, that obesity drug developer Kailera Therapeutics and proteomics firm Alamar... Keep Reading...
Transparent blue cells with dark centers floating against a vibrant blue background.

Biotech and Pharma Market Update: Q1 2026 in Review

After a strong performance toward the end of 2025, the life science sector began the new year on a constructive note. Looking forward, signals in Q1 point to a market continuing to reward proof over promise. In an interview with the Investing News Network (INN), Eric Shrayer, partner and... Keep Reading...
A glass flask on a reflective table with overlaid stock market charts and numerical data, including text reading: 0.00%.

Anthropic Inks US$400 Million Deal for AI Biotech Startup Coefficient Bio

AI developer Anthropic is acquiring New York-based biotech startup Coefficient Bio for approximately US$400 million, according to The Information.Founded just last fall and operating largely in stealth, Coefficient Bio will be absorbed directly into Anthropic’s healthcare life sciences... Keep Reading...
Lexaria Applauds Eli Lilly's Foundayo Drug Approval

Lexaria Applauds Eli Lilly's Foundayo Drug Approval

The number of oral weight-loss / diabetes drug treatments is expanding, increasing demand for the reduction of side effects KELOWNA, BC / ACCESS Newswire / April 7, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is... Keep Reading...

Interactive Chart

Latest Press Releases

Related News